Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, and BridgeBio Oncology Therapeutics have announced that they expect to raise approximately $382 million in gross proceeds from their business combination. This includes $120 million from Helix's trust account and around $261 million from a private placement $(PIPE)$ transaction. The PIPE financing was led by Cormorant Asset Management and features participation from several prominent investment groups. Helix retained over 60% of its trust account funds following redemptions by public shareholders. The companies plan to move swiftly towards closing the transaction once all conditions are met.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Helix Acquisition Corp. II published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9507105-en) on August 06, 2025, and is solely responsible for the information contained therein.